Skin And Skin Structure Infections (SSSI) is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Skin And Skin Structure Infections (SSSI) have a 86.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Skin And Skin Structure Infections (SSSI) compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Skin And Skin Structure Infections (SSSI) overview
Skin and skin-structure infections (SSSIs) are infections of the epidermis, dermis or subcutaneous tissue. SSSIs, also referred to as skin and soft tissue infections (SSTIs) or acute bacterial skin and skin structure infections (ABSSSIs) of skin and associated soft tissues (such as loose connective tissue and mucous membranes). SSSI are common presentations in bacterial diseases ,most common are S. aureus and S. pyogenes.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Skin And Skin Structure Infections (SSSI), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.